Using Circulating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-Associated Oropharyngeal Cancer

What is the Purpose of this Study?

The purpose of this study is to determine whether using less intense radiation therapy and chemotherapy (chemoradiation) after trans-oral robotic surgery (TORS) will be as effective in treating HPV-associated oropharyngeal cancer as standard treatment while also reducing side effects. Patients will receive 3, 4, or 5 weeks of treatment depending on the extent of the disease at the time of surgery and the presence or absence of tumor tissue in the blood after the completion of surgery, instead of the standard 6-6.5 weeks of treatment. The chemotherapy drugs used in this study (cisplatin, or carboplatin and paclitaxel, if applicable) are approved by the U.S. Food and Drug Administration (FDA).


Eligibility

Not Available


Where can I participate?

  • CS Cancer Tarzana
  • CS Cancer at Beverly Hills
  • CS Cancer at Cedars-Sinai Medical Center
  • CS Cancer at The Angeles Clinic and Research Institute
  • Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer



What is the full name of this clinical trial?

IIT2023-14-Zumsteg-ULTRA-HPV: Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Study Details
Disease Type/Condition

Other

Principal Investigator

Zumsteg, Zachary

Co-Investigators

Allen Ho, Andrew Horodner, Andrew Schumacher, Ani Balmanoukian, Benjamin King, Bryan Chang, Cathie T Chung, David Chan, David Hoffman, Evan Walgama, Hugo Hool, Inderjit Mehmi, Jeremy Lorber, Johnny Chang, Jon Mallen-St. Clair, Julie Jang, Jun Gong, Justin Moyers, Justin Wayne Tiulim, Kevin Scher, Kristopher Wentzel, Marc Botnick, Navid Hafez, Omid Hamid, Rebecca Philipson, Robert Reznik, Ryan Ponec, Stephen Shiao, Swati Sikaria, Syed Jilani, Thomas Lowe, Thyra Endicott, Usama Mahmood, Vanessa Dickey, Vi K. Chiu

Age Group

Adult

Phase

II

IRB Number

STUDY00003638


How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Other

Principal Investigator

Zumsteg, Zachary

Age Group

Adult

Phase

II

IRB Number

IIT2023-14-ZUMSTEG-ULTRA-HPV


Contact
Email
clinicaltrials@cshs.org